Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18991315 | Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof | December 2024 | March 2025 | Allow | 3 | 1 | 0 | No | No |
| 18628200 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS | April 2024 | February 2025 | Allow | 11 | 1 | 0 | No | No |
| 18592208 | METHODS OF TREATING TUMOR | February 2024 | March 2025 | Allow | 12 | 1 | 0 | No | No |
| 18408377 | METHODS OF USING ANTI-SP17 IMMUNOTHERAPEUTICS | January 2024 | November 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18396461 | ANTI-TSPAN8/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-TSPAN8 ANTIBODY | December 2023 | January 2025 | Allow | 13 | 1 | 0 | No | No |
| 18542441 | T CELL RECEPTORS AND FUSION PROTEINS THEREOF | December 2023 | April 2024 | Allow | 4 | 0 | 0 | No | No |
| 18537973 | COMPOSITION OF BL-8040 | December 2023 | October 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18532450 | SYSTEMS AND METHODS FOR BARRETT'S ESOPHAGUS PATHOGENESIS AND ESOPHAGEAL ADENOCARCINOMA PROGRESSION REVEALING MARKERS | December 2023 | March 2025 | Allow | 16 | 2 | 1 | No | No |
| 18531287 | DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES | December 2023 | August 2024 | Abandon | 8 | 0 | 0 | No | No |
| 18529758 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | December 2023 | February 2025 | Allow | 14 | 2 | 0 | No | No |
| 18516168 | RESPONSE TO EGFR BLOCKADE | November 2023 | April 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18487818 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NONCODING RNA OVERLAPPING THE LCK GENE THAT REGULATES PROSTATE CANCER CELL GROWTH | October 2023 | April 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18475552 | Anti-TIM-3 Antibodies and Use Thereof | September 2023 | February 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18471388 | HUMANIZED ANTI-IL-1R3 ANTIBODY AND METHODS OF USE | September 2023 | March 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18462648 | OVARIAN CANCER VACCINES | September 2023 | March 2025 | Allow | 18 | 2 | 0 | No | No |
| 18463209 | HETERODIMERIC PROTEINS | September 2023 | May 2025 | Allow | 20 | 1 | 0 | No | No |
| 18459857 | Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof | September 2023 | June 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18456044 | NOVEL THI-INDUCING ADJUVANT COMPRISING COMBINATION OF DIFFERENT NUCLEIC ACID ADJUVANTS AND USE OF SAME | August 2023 | May 2025 | Allow | 21 | 3 | 0 | No | No |
| 18263430 | ANTI-NECTIN-4-ANTIBODIES AND USES THEREOF | July 2023 | March 2024 | Allow | 8 | 1 | 0 | No | No |
| 18270521 | COMPOSITION OF BL-8040 | June 2023 | January 2025 | Allow | 19 | 1 | 0 | No | No |
| 18340774 | NEUROPILIN-1-PEPTIDE BASED ANTIBODY, HIGHLIGHTING NEW EPITOPE ASSOCIATED TO GLYCOSAMINOGLYCAN-MODIFIED NEUROPILIN-1 AND METHODS OF USE THEREOF | June 2023 | December 2023 | Allow | 5 | 0 | 0 | No | No |
| 18213132 | HUMANIZED CC CHEMOKINE RECEPTOR 4 (CCR4) ANTIBODIES AND METHODS OF USE THEREOF | June 2023 | February 2025 | Allow | 20 | 2 | 0 | No | No |
| 18211038 | Methods of Assaying Neoplastic and Neoplasia-Related Cells and Uses Thereof | June 2023 | January 2025 | Allow | 19 | 2 | 0 | No | No |
| 18325497 | BIOMARKERS FOR CANCER IMMUNOTHERAPY OUTCOMES | May 2023 | January 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18200000 | ANTITUMOR PHARMACEUTICAL COMPOSITION COMPRISING AZVUDINE AND CHEMOTHERAPEUTIC AGENT | May 2023 | January 2025 | Allow | 20 | 6 | 0 | No | No |
| 18036610 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NONCODING RNA OVERLAPPING THE LCK GENE THAT REGULATES PROSTATE CANCER CELL GROWTH | May 2023 | May 2025 | Abandon | 25 | 2 | 0 | Yes | No |
| 18308623 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS | April 2023 | March 2025 | Allow | 22 | 1 | 1 | No | No |
| 18134293 | METHODS OF TREATING COLON CANCER USING NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPY | April 2023 | December 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18133822 | TREATMENT OF CANCER WITH ANTI-GITR AGONIST ANTIBODIES | April 2023 | September 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18298807 | THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS | April 2023 | October 2024 | Allow | 18 | 1 | 0 | No | No |
| 18126275 | SYNTHETIC LETHALITY AND THE TREATMENT OF CANCER | March 2023 | March 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18186762 | Immunotherapy Methods for Patients Whose Tumors Carry a High Passenger Gene Mutation Burden | March 2023 | October 2024 | Allow | 19 | 1 | 0 | No | No |
| 18185736 | IMMUNOMODULATORY ANTIBODIES AND METHODS OF USE THEREOF | March 2023 | August 2024 | Allow | 17 | 1 | 0 | No | No |
| 18175420 | ANTIBODIES AGAINST TIM3 AND USES THEREOF | February 2023 | January 2025 | Allow | 23 | 2 | 0 | No | No |
| 18173417 | DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES | February 2023 | January 2024 | Abandon | 11 | 0 | 0 | No | No |
| 18171569 | METHODS OF DETECTING PROSTATE CANCER | February 2023 | August 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 18164417 | CHIMERIC ILT RECEPTOR COMPOSITIONS AND METHODS | February 2023 | February 2025 | Allow | 24 | 3 | 0 | Yes | No |
| 18163723 | BIOMARKERS FOR PREDICTING TUMOR RESPONSE TO AND TOXICITY OF IMMUNOTHERAPY | February 2023 | January 2025 | Allow | 23 | 1 | 0 | No | No |
| 18157717 | PREDICTIVE AND DIAGNOSTIC METHODS FOR PROSTATE CANCER | January 2023 | August 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18151297 | APTAMER BASED AFFINITY CAPTURE METHODS FOR THE SELECTIVE ENRICHMENT OF HUMAN IMMUNOGLOBULIN FC DOMAINS | January 2023 | April 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18149881 | MIR-3132 UPREGULATION OF THE TRAIL PATHWAY AND APOPTOTIC ACTIVITY IN CANCER CELLS | January 2023 | April 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18082368 | NANOPARTICLES AND DISTINCT EXOSOME SUBSETS FOR DETECTION AND TREATMENT OF CANCER | December 2022 | November 2024 | Allow | 23 | 2 | 1 | No | No |
| 18078088 | WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES | December 2022 | December 2024 | Abandon | 24 | 1 | 0 | No | No |
| 18062419 | DETECTING NEOPLASM | December 2022 | March 2024 | Allow | 15 | 1 | 0 | No | No |
| 18057627 | Novel Method For Producing Low Viscous And Highly Concentrated Biopharmaceutical Drug Products In Liquid Formulation | November 2022 | March 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18054307 | METHODS FOR THE DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA | November 2022 | June 2025 | Abandon | 31 | 4 | 0 | No | No |
| 18047285 | VIRUS COMPOSITION | October 2022 | August 2024 | Allow | 22 | 1 | 1 | No | No |
| 18047216 | METHODS OF TREATING TUMOR | October 2022 | October 2023 | Allow | 12 | 1 | 0 | Yes | No |
| 18046565 | NON-INVASIVE TEST TO PREDICT RESPONSE TO THERAPY IN COLORECTAL CANCER PATIENTS | October 2022 | October 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17932259 | CHIMERIC ANTIGEN RECEPTOR AND METHODS OF USE THEREOF | September 2022 | August 2024 | Allow | 23 | 2 | 0 | No | No |
| 17940883 | PLASMA AUTOANTIBODY BIOMARKERS FOR BASAL LIKE BREAST CANCER | September 2022 | May 2024 | Allow | 20 | 1 | 2 | No | No |
| 17817886 | IMMUNE-STIMULATING IL-2 FUSION PROTEINS | August 2022 | May 2023 | Allow | 10 | 2 | 0 | Yes | No |
| 17817862 | DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES | August 2022 | May 2023 | Abandon | 9 | 0 | 0 | No | No |
| 17848694 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS | June 2022 | November 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17846966 | BIOMARKERS AND USES THEREOF FOR SELECTING IMMUNOTHERAPY INTERVENTION | June 2022 | April 2024 | Abandon | 21 | 1 | 1 | Yes | No |
| 17843852 | METHODS OF TREATING FIBROBLAST GROWTH FACTOR 19-MEDIATED CANCERS AND TUMORS | June 2022 | June 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17806218 | CD3/CD38 T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS AND METHODS OF THEIR PRODUCTION | June 2022 | February 2024 | Allow | 20 | 2 | 0 | No | No |
| 17805336 | CANCER TREATMENT | June 2022 | July 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17826477 | BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT RESPONSE | May 2022 | April 2025 | Allow | 35 | 3 | 1 | No | No |
| 17752519 | WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES | May 2022 | September 2022 | Allow | 3 | 1 | 0 | No | No |
| 17744262 | METHODS FOR TREATMENT OF CD20-POSITIVE PROLIFERATIVE DISORDER WITH MOSUNETUZUMAB AND POLATUZUMAB VEDOTIN | May 2022 | February 2025 | Allow | 33 | 4 | 0 | No | No |
| 17739317 | TCR, POLYPEPTIDE, EXPRESSION VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION AND METHOD FOR OBTAINING TCR | May 2022 | November 2024 | Allow | 31 | 3 | 1 | No | No |
| 17739308 | HUMANIZED, MOUSE OR CHIMERIC ANTI-CD47 MONOCLONAL ANTIBODIES | May 2022 | April 2024 | Allow | 24 | 1 | 0 | Yes | No |
| 17736475 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38 | May 2022 | June 2024 | Allow | 25 | 1 | 1 | No | No |
| 17722051 | NON-CODING RNA FOR DETECTION OF CANCER | April 2022 | November 2023 | Abandon | 19 | 3 | 0 | Yes | No |
| 17654801 | Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases | March 2022 | September 2023 | Allow | 18 | 1 | 0 | No | No |
| 17690634 | METHODS FOR THE TREATMENT OF CANCER | March 2022 | June 2024 | Abandon | 27 | 2 | 0 | No | No |
| 17639783 | ANTI-TSPAN8/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-TSPAN8 ANTIBODY | March 2022 | September 2023 | Allow | 19 | 0 | 0 | No | No |
| 17673718 | NOVEL ESTROGEN RECEPTOR MUTATIONS AND USES THEREOF | February 2022 | June 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17650360 | COMPOSITION AND PROCESS FOR PREPARING VACCINE | February 2022 | April 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17588262 | HETERO-DIMERIC MULTI-SPECIFIC ANTIBODY FORMAT | January 2022 | August 2023 | Allow | 19 | 1 | 0 | No | No |
| 17597706 | IMMUNOMODULATORY ANTIBODIES AND METHODS OF USE THEREOF | January 2022 | December 2022 | Allow | 11 | 1 | 0 | No | No |
| 17568738 | BISPECIFIC SINGLE-CHAIN ANTIBODY, RECOMBINANT ONCOLYTIC VIRUS FOR EXPRESSING SAME AND VIRUS COMPOSITION | January 2022 | August 2022 | Allow | 8 | 2 | 0 | Yes | No |
| 17620209 | ANTI-CD53 COMPOSITIONS AND METHODS FOR MODULATING MYELOID CELL INFLAMMATORY PHENOTYPES AND USES THEREOF | December 2021 | May 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17542342 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS | December 2021 | November 2023 | Allow | 24 | 1 | 1 | No | No |
| 17542341 | HETERODIMERIC ANTIBODIES THAT BIND SOMATOSTATIN RECEPTOR 2 | December 2021 | April 2024 | Allow | 28 | 1 | 1 | No | No |
| 17615735 | PD-1 AXIS BINDING ANTAGONIST TO TREAT CANCER WITH GENETIC MUTATIONS IN SPECIFIC GENES | December 2021 | June 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17539030 | MARKER COMPOSITION FOR DIAGNOSING OR PREDICTING PROGNOSIS OF LUNG CANCER BASED ON EXOSOME OVEREXPRESSING GCC2 GENE OR PROTEIN | November 2021 | January 2024 | Allow | 26 | 2 | 0 | No | No |
| 17615535 | MULTI-TUMOR GENE SIGNATURE FOR SUITABILITY TO IMMUNO-ONCOLOGY THERAPY | November 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17526817 | ANTI-TIM-3 ANTIBODIES AND USE THEREOF | November 2021 | November 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17609517 | Cancer stratification and treatment based on Inhibition of NOD-2 | November 2021 | June 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17515227 | TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS | October 2021 | December 2023 | Allow | 25 | 2 | 0 | No | No |
| 17504452 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS | October 2021 | August 2023 | Allow | 22 | 1 | 0 | No | No |
| 17501576 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | October 2021 | July 2023 | Allow | 21 | 1 | 0 | No | No |
| 17489885 | ANTIBODY BINDING TO CARBONIC ANHYDRASE AND USE THEREOF | September 2021 | August 2023 | Allow | 22 | 2 | 0 | No | No |
| 17471526 | Treatment of Parkinson's Disease | September 2021 | May 2024 | Allow | 32 | 1 | 0 | No | No |
| 17465968 | ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES AND USES THEREOF | September 2021 | October 2023 | Allow | 26 | 1 | 1 | No | No |
| 17434359 | APOE GENOTYPING IN CANCER PROGNOSTICS AND TREATMENT | August 2021 | January 2025 | Allow | 41 | 2 | 1 | No | No |
| 17407264 | BINDING MOLECULE SPECIFIC FOR LIF AND USE THEREOF | August 2021 | April 2024 | Allow | 32 | 5 | 1 | No | No |
| 17404025 | OVARIAN CANCER VACCINES | August 2021 | June 2023 | Allow | 21 | 1 | 0 | No | No |
| 17393892 | METHODS FOR CAPTURING, ISOLATION, AND TARGETING OF CIRCULATING TUMOR CELLS AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS THEREOF | August 2021 | October 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17443780 | Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof | July 2021 | October 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17383975 | INHIBITORS OF ALPHA-TUBULIN ACETYLATION FOR THE TREATMENT OF PAIN | July 2021 | July 2023 | Allow | 24 | 1 | 0 | No | No |
| 17379878 | NOVEL METHOD FOR MONITORING AND TREATING ORAL CANCER | July 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17422227 | USE OF AGENTS CAPABLE OF INDUCING LC3-ASSOCIATED PHAGOCYTOSIS FOR TREATING SUSTAINED INFLAMMATION IN PATIENTS SUFFERING FROM CHRONIC LIVER DISEASE | July 2021 | March 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17368674 | TUMOR MICROENVIRONMENT-BASED METHODS FOR ASSESSING CAR-T AND OTHER IMMUNOTHERAPIES | July 2021 | September 2022 | Allow | 15 | 3 | 0 | Yes | No |
| 17366769 | Method For Determining Responsiveness To Prostate Cancer Treatment | July 2021 | December 2023 | Allow | 29 | 1 | 1 | No | No |
| 17359100 | WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES | June 2021 | February 2022 | Allow | 8 | 1 | 0 | Yes | No |
| 17358277 | CONTORSBODY - A SINGLE CHAIN TARGET BINDER | June 2021 | September 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17353013 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS | June 2021 | July 2023 | Allow | 25 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner AEDER, SEAN E.
With a 48.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner AEDER, SEAN E works in Art Unit 1642 and has examined 1,611 patent applications in our dataset. With an allowance rate of 52.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner AEDER, SEAN E's allowance rate of 52.6% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by AEDER, SEAN E receive 2.33 office actions before reaching final disposition. This places the examiner in the 80% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by AEDER, SEAN E is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +26.2% benefit to allowance rate for applications examined by AEDER, SEAN E. This interview benefit is in the 77% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.1% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 43.1% of cases where such amendments are filed. This entry rate is in the 59% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 52.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 44% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 75.2% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 73.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 74.0% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 6.2% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 56% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.